UBTD2 Inhibitors
Inhibitors of UBTD2 function by altering the ubiquitin-proteasome system and related post-translational modifications, which are critical for various cellular processes, including protein degradation. Some inhibitors specifically target the proteasome, leading to the accumulation of polyubiquitylated proteins, thus potentially saturating UBTD2's ability to facilitate protein turnover. This saturation can result in a functional blockade of UBTD2's activity, disrupting its role in ubiquitin-mediated pathways. Other inhibitors act upstream, affecting the enzymes responsible for the ubiquitination process itself. By inhibiting ubiquitin-activating enzyme E1 or the NEDD8-activating enzyme, these compounds indirectly reduce the functional activity of UBTD2. The disruption of ubiquitin and neddylation processes results in an imbalance that impedes UBTD2's function in these post-translational modifications. Furthermore, the alteration of the ubiquitin pool through the inhibition of specific deubiquitinating enzymes can also affect UBTD2's role within the ubiquitin-proteasome pathway.
Additionally, certain inhibitors target the recognition and binding of ubiquitylated substrates to the proteasome. By preventing this critical step in protein degradation, these compounds indirectly inhibit UBTD2 by interfering with the normal function of the ubiquitin-proteasome system. Alkylating agents that modify cysteine residues can inhibit thiol-dependent enzymes, leading to a disruption of proteins involved in the ubiquitination cascade. This inhibition can affect the ubiquitin cascade itself, essential for UBTD2's role in targeting proteins for degradation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
This proteasome inhibitor leads to the accumulation of ubiquitylated proteins, which can disrupt various cellular processes, including those that UBTD2 is involved in. The excessive ubiquitylated proteins can saturate UBTD2's function, leading to its functional inhibition as UBTD2 is a ubiquitin domain-containing protein that may play a role in ubiquitin-mediated pathways. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
As an inhibitor of the proteasome and ubiquitin-proteasome pathway, MG-132 results in the accumulation of polyubiquitylated proteins. This accumulation can indirectly inhibit UBTD2 function by overwhelming the degradation pathway that UBTD2 may facilitate, leading to a functional blockade of its activity in protein turnover. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
This irreversible inhibitor of ubiquitin-activating enzyme E1 can suppress the ubiquitination process. By inhibiting upstream ubiquitination, PYR-41 indirectly inhibits UBTD2 as it may disrupt the availability of ubiquitylated substrates for UBTD2, thereby reducing its functional activity in the ubiquitin system. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
MLN 4924 inhibits the NEDD8-activating enzyme, which is necessary for neddylation, a process related to ubiquitination. By inhibiting this process, MLN 4924 can indirectly inhibit UBTD2 by disrupting the balance of ubiquitination and neddylation processes that UBTD2 might be involved in, impacting its functional role in these post-translational modifications. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
By irreversibly binding to and inhibiting the proteasome, this compound causes the accumulation of ubiquitylated proteins. This may indirectly inhibit the functional activity of UBTD2 by saturating the ubiquitin-proteasome system that UBTD2 is associated with, possibly leading to its functional inhibition. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
As a selective proteasome inhibitor, Epoxomicin causes the build-up of ubiquitylated proteins, potentially inhibiting UBTD2's function indirectly by impairing the proteasomal degradation pathway, which UBTD2 may be involved in. | ||||||
IU1 | 314245-33-5 | sc-361215 sc-361215A sc-361215B | 10 mg 50 mg 100 mg | $138.00 $607.00 $866.00 | 2 | |
IU1 is an inhibitor of the deubiquitinating enzyme USP14, which can lead to an altered ubiquitin-proteasome pathway. The inhibition of USP14 can affect the ubiquitin pool and potentially the function of UBTD2 by disrupting the normal cycling of ubiquitin and its related proteins, thus indirectly inhibiting UBTD2's role in the pathway. | ||||||
N-Ethylmaleimide | 128-53-0 | sc-202719A sc-202719 sc-202719B sc-202719C sc-202719D | 1 g 5 g 25 g 100 g 250 g | $22.00 $68.00 $210.00 $780.00 $1880.00 | 19 | |
An alkylating agent that inhibits thiol-dependent enzymes and proteins. By modifying cysteine residues, it can disrupt the function of proteins involved in the ubiquitination process. This can lead to an indirect inhibition of UBTD2 by affecting the ubiquitin cascade, which is essential for the functional activity of UBTD2 in targeting proteins for degradation. | ||||||